OR WAIT null SECS
Horizon announces new bioproduction outlicense deal with an unnamed partner for a minimum value of £500,000.
Horizon Discovery Group, a provider of precision engineered off the shelf and custom CHO cell lines used for the manufacture of biological therapeutics, announced that it has signed a licensing agreement with an undisclosed commercial partner for access to Horizon bioproduction cell lines. The subscription-based deal, a first of its kind for Horizon, is valued at a minimum of £500,000.
Under the terms of the license, the partner will be given access to one of Horizon’s engineered cell lines (CHO SOURCE GS Null cell line), for an indefinite period of time, to manufacture their novel therapeutics.
The partner will also gain early access to Horizon’s program of continuous cell line innovation, enabling them to license, via the subscription, any follow-on cell lines developed as part of the program at a 50% discount within a five-year period from signing of the agreement. The minimum fee will be paid up front, with a significant amount to be recognized in FY2016.